ENDRA Life Sciences (NASDAQ:NDRA) Shares Down 7.1% – Here’s Why

ENDRA Life Sciences Inc. (NASDAQ:NDRA) shares dropped 7.1% on Friday. The stock traded as low as $4.74 and last traded at $4.74. 14,349 shares were traded during mid-day trading, a decline of 42% from the average session volume of 24,664 shares. The stock had previously closed at $5.10.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of ENDRA Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $25.00.

ENDRA Life Sciences Price Performance

The company has a market capitalization of $7.11 million, a P/E ratio of -0.74 and a beta of -0.09. The business has a 50-day moving average of $5.41 and a 200-day moving average of $5.16.

ENDRA Life Sciences (NASDAQ:NDRA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.21. Sell-side analysts predict that ENDRA Life Sciences Inc. will post -4.11 EPS for the current fiscal year.

Institutional Investors Weigh In On ENDRA Life Sciences

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Citizens Financial Group Inc. RI purchased a new position in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 28,400 shares of the company’s stock, valued at approximately $151,000. Citizens Financial Group Inc. RI owned 2.24% of ENDRA Life Sciences at the end of the most recent quarter. Institutional investors and hedge funds own 1.19% of the company’s stock.

About ENDRA Life Sciences

ENDRA Life Sciences Corp. (NASDAQ: NDRA) is a medical technology company developing noninvasive diagnostic imaging systems. The company’s primary technology is Thermo-Acoustic Enhanced UltraSound (TAEUS), a platform designed to expand the capabilities of conventional ultrasound by using radiofrequency energy and ultrasound imaging to characterize tissue properties.

ENDRA is initially focused on applying TAEUS to the assessment of liver fat, including fatty liver disease. Its system is intended to provide quantitative information about hepatic steatosis and potentially other tissue characteristics without requiring an invasive biopsy or the use of more costly imaging modalities.